New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
Subscribe To Our Newsletter & Stay Updated